Alon Bloomenfeld
CEO
Claimed by owner Raziel Therapeutics
Former names:
Injectable Drug for Treatment of Obesity
Raziel Therapeutics
www.calcalistech.com
•
Sep 22, 2020
Double-chin reducing Israeli startup closes $74 million China licensing deal
en.globes.co.il
•
Dec 18, 2019
Fat disorder drug co Raziel Therapeutics raises $22m
www.jpost.com
•
Dec 10, 2018
https://www.jpost.com/Special-Content/How-Israeli-Technology-is-Changing-Healthcare-574021
www.timesofisrael.com
•
Nov 29, 2017
Israeli 'fat-melting' injection claims to help battle obesity
www.pontifax.com
•
Jul 20, 2016
Portfolio - Pontifax Venture Capital
About
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new chemical entity that converts white adipose tissue (WAT) into brown adipose tissue (BAT) after a single injection into subcutaneous fat, potentially providing a new way to treat people who are overweight or obese.
Raziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue.
The companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues.
In November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.
Raziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue.
The companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues.
In November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
RZL-012
Geographic markets
Israel, China
News
(5)
www.calcalistech.com
•
Sep 22, 2020
Double-chin reducing Israeli startup closes $74 million China licensing deal
en.globes.co.il
•
Dec 18, 2019
Fat disorder drug co Raziel Therapeutics raises $22m
www.jpost.com
•
Dec 10, 2018
https://www.jpost.com/Special-Content/How-Israeli-Technology-is-Changing-Healthcare-574021
www.timesofisrael.com
•
Nov 29, 2017
Israeli 'fat-melting' injection claims to help battle obesity
www.pontifax.com
•
Jul 20, 2016
Portfolio - Pontifax Venture Capital
The Team
(3)
AB
EB
Eran Blaugrand
VP R&D
RG
Racheli Gueta
Clinical Trials Manager
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
$600K
Dec 2014
2 Investors
$600K
A Round
$4.5M
Feb 2016
2 Investors
$4.5M
C Round
$22M
Dec 2019
6 Investors
$22M
Others
Academic Techonology
Aug 2012
undefined
Proprietary drug for targeted fat reduction
Media gallery
(0)Locations
Israel
Prof. Menahem Plaut Street 10, Rehovot, Israel
Locations
Israel
Prof. Menahem Plaut Street 10, Rehovot, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,